Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.
Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps for Immunoscore in oncology.
Immunoscore has demonstrated predictive value for treatment durations with FOLFOX among patients with early-stage colorectal cancer (CRC). At the 2019 ASCO Annual Meeting, Galon reported that patients with an intermediate or high Immunoscore responded better to 6 months of FOLFOX, whereas patients with a low Immunoscore did not derive any additional benefit from 6 months of treatment over 3 months of treatment.
If Immunoscore is to have widespread utility, the relevance of a patient’s preexisting immunity must be validated in other indications, says Galon. Although these trials are ongoing, Galon anticipates that Immunoscore will be very relevant to several tumor types. Moreover, Immunoscore has the potential to show predictive value for various therapeutic modalities, including immunotherapy and CAR T-cell therapy, in solid tumors and hematologic malignancies alike, he concludes.